Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

Antibody Engineering & Therapeutics Europe
1 - 3 June, 2027
Congress CenterBasel Switzerland
Menu

Tiffany Thorn
Founder and CEO at BiVictriX Therapeutics
Speaker

Profile

Tiffany Thorn is an experienced life sciences executive with over a decade of industry experience in the discovery and development of next-generation Antibody Drug Conjugates (ADCs). As Founder and CEO of BiVictriX Therapeutics, she has been pivotal to spearheading the development strategy for the company’s proprietary Bi-Cygni® approach – an innovate bispecific ADC approach inspired by her earlier career in clinical science.

Agenda Sessions

  • Conditional Logic-Gated Bispecific ADCs: Harnessing Novel Dual Antigen Fingerprints to Expand Efficacy & Minimise On-Target/Off-Tissue Toxicity

    , 14:35
    View Session

At this event

Prev
Next
Niccolo Pengo, PhD
Chief Scientific Officer
Mabylon AG

See Tiffany at Antibody Engineering & Therapeutics Europe